Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.16
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.66 -0.37%
EPS Growth %: -133.3%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -133.3%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.16). Revenue for the quarter came in at $24.84 million versus the consensus estimate of $10.22 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Labcorp acquires MLM Medical Labs to expand lab network
- HSBC lifts S&P 500 year-end target
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
